{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:58:11Z","timestamp":1788022691967,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Wenzhou Major Program of Science and Technology Innovation","award":["Grant No. ZY2020012"],"award-info":[{"award-number":["Grant No. ZY2020012"]}]},{"name":"Health Foundation for Creative Talents in Zhejiang Province","award":["(Grant No. 2016"],"award-info":[{"award-number":["(Grant No. 2016"]}]},{"name":"Project Foundation for the College Young and Middle-aged Academic Leader of Zhejiang Province","award":["Grant No. 2017"],"award-info":[{"award-number":["Grant No. 2017"]}]},{"name":"Basic Research Project of Wenzhou","award":["Grant No. Y2020164"],"award-info":[{"award-number":["Grant No. Y2020164"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-022-01541-1","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T10:02:55Z","timestamp":1661508175000},"page":"1170-1178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with 18F-PSMA-1007 PET: comparison among different volume segmentation thresholds"],"prefix":"10.1007","volume":"127","author":[{"given":"Fei","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-2417","authenticated-orcid":false,"given":"Yunjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"issue":"3","key":"1541_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1541_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236026","author":"P Guglielmo","year":"2021","unstructured":"Guglielmo P, Marturano F, Bettinelli A, Gregianin M, Paiusco M, Evangelista L (2021) Additional value of PET radiomic features for the initial staging of prostate cancer: a systematic review from the literature. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13236026","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1541_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.crad.2020.06.031","volume":"75","author":"RW Foley","year":"2020","unstructured":"Foley RW, Redman SL, Graham RN, Loughborough WW, Little D (2020) Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol 75(12):903\u2013913. https:\/\/doi.org\/10.1016\/j.crad.2020.06.031","journal-title":"Clin Radiol"},{"issue":"1","key":"1541_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1464-410X.2008.08059.x","volume":"103","author":"AS Moussa","year":"2009","unstructured":"Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS (2009) Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 103(1):43\u201348. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.08059.x","journal-title":"BJU Int"},{"key":"1541_CR5","doi-asserted-by":"publisher","first-page":"341324","DOI":"10.1155\/2014\/341324","volume":"2014","author":"AM Hoogland","year":"2014","unstructured":"Hoogland AM, Kweldam CF, van Leenders GJ (2014) Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review. BioMed Res Int 2014:341324. https:\/\/doi.org\/10.1155\/2014\/341324","journal-title":"BioMed Res Int"},{"issue":"11","key":"1541_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969\u2013974. https:\/\/doi.org\/10.1001\/jama.280.11.969","journal-title":"JAMA"},{"issue":"2","key":"1541_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2014.06.015","volume":"67","author":"BC Jeong","year":"2015","unstructured":"Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M (2015) The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. Eur Urol 67(2):342\u2013346. https:\/\/doi.org\/10.1016\/j.eururo.2014.06.015","journal-title":"Eur Urol"},{"issue":"1","key":"1541_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/s0022-5347(17)57411-x","volume":"119","author":"AM Kwart","year":"1978","unstructured":"Kwart AM, Sims JE (1978) Blood vascular invasion: a poor prognostic factor in adenocarcinoma of the prostate. J Urol 119(1):138\u2013140. https:\/\/doi.org\/10.1016\/s0022-5347(17)57411-x","journal-title":"J Urol"},{"issue":"6","key":"1541_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/apm.12533","volume":"124","author":"L Egevad","year":"2016","unstructured":"Egevad L, Delahunt B, Srigley JR, Samaratunga H (2016) International Society of Urological Pathology (ISUP) grading of prostate cancer\u2014an ISUP consensus on contemporary grading. APMIS Acta Pathol Microbiol Immunol Scand 124(6):433\u2013435. https:\/\/doi.org\/10.1111\/apm.12533","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"issue":"5\u20136","key":"1541_CR10","doi-asserted-by":"publisher","first-page":"E293","DOI":"10.5489\/cuaj.11224","volume":"7","author":"EC Serefoglu","year":"2013","unstructured":"Serefoglu EC, Altinova S, Ugras NS, Akincioglu E, Asil E, Balbay MD (2013) How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Can Urol Assoc J J l\u2019Assoc Urol Can 7(5\u20136):E293-298. https:\/\/doi.org\/10.5489\/cuaj.11224","journal-title":"Can Urol Assoc J J l'Assoc Urol Can"},{"issue":"5","key":"1541_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.21037\/tau.2018.08.03","volume":"7","author":"M Czarniecki","year":"2018","unstructured":"Czarniecki M, Mena E, Lindenberg L, Cacko M, Harmon S, Radtke JP, Giesel F, Turkbey B, Choyke PL (2018) Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. Transl Androl Urol 7(5):831\u2013843. https:\/\/doi.org\/10.21037\/tau.2018.08.03","journal-title":"Transl Androl Urol"},{"issue":"1","key":"1541_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ph13010012","volume":"13","author":"C Zippel","year":"2020","unstructured":"Zippel C, Ronski SC, Bohnet-Joschko S, Giesel FL, Kopka K (2020) Current status of PSMA-Radiotracers for prostate cancer: data analysis of prospective trials listed on ClinicalTrials.gov. Pharmaceuticals (Basel, Switzerland) 13(1):12. https:\/\/doi.org\/10.3390\/ph13010012","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"4","key":"1541_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","volume":"49","author":"HJ Wester","year":"2019","unstructured":"Wester HJ, Schottelius M (2019) PSMA-targeted radiopharmaceuticals for imaging and therapy. Sem Nucl Med 49(4):302\u2013312. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.02.008","journal-title":"Sem Nucl Med"},{"issue":"9","key":"1541_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.21037\/atm-20-6446","volume":"9","author":"S Moazemi","year":"2021","unstructured":"Moazemi S, Erle A, Khurshid Z, Lutje S, Muders M, Essler M, Schultz T, Bundschuh RA (2021) Decision-support for treatment with (177)Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET\/CT and clinical parameters. Ann Transl Med 9(9):818. https:\/\/doi.org\/10.21037\/atm-20-6446","journal-title":"Ann Transl Med"},{"issue":"7","key":"1541_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00259-018-3954-y","volume":"45","author":"L Thomas","year":"2018","unstructured":"Thomas L, Kantz S, Hung A, Monaco D, Gaertner FC, Essler M, Strunk H, Laub W, Bundschuh RA (2018) (68)Ga-PSMA-PET\/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost. Eur J Nucl Med Mol Imaging 45(7):1170\u20131178. https:\/\/doi.org\/10.1007\/s00259-018-3954-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1541_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schoder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K (2017) (68)Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44(6):1014\u20131024. https:\/\/doi.org\/10.1007\/s00259-017-3670-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1541_CR17","doi-asserted-by":"publisher","first-page":"e1169","DOI":"10.1002\/cnr2.1169","volume":"2","author":"S Sengupta","year":"2019","unstructured":"Sengupta S, Asha Krishnan M, Chattopadhyay S, Chelvam V (2019) Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. Cancer Rep (Hoboken, NJ) 2(4):e1169. https:\/\/doi.org\/10.1002\/cnr2.1169","journal-title":"Cancer Rep (Hoboken, NJ)"},{"issue":"3","key":"1541_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/diagnostics11030552","volume":"11","author":"S Awenat","year":"2021","unstructured":"Awenat S, Piccardo A, Carvoeiras P, Signore G, Giovanella L, Prior JO, Treglia G (2021) Diagnostic role of (18)F-PSMA-1007 PET\/CT in prostate cancer staging: a systematic review. Diagnostics (Basel) 11(3):552. https:\/\/doi.org\/10.3390\/diagnostics11030552","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"1541_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","volume":"278","author":"RJ Gillies","year":"2016","unstructured":"Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278(2):563\u2013577. https:\/\/doi.org\/10.1148\/radiol.2015151169","journal-title":"Radiology"},{"issue":"4","key":"1541_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/diagnostics11040594","volume":"11","author":"A Damascelli","year":"2021","unstructured":"Damascelli A, Gallivanone F, Cristel G, Cava C, Interlenghi M, Esposito A, Brembilla G, Briganti A, Montorsi F, Castiglioni I, De Cobelli F (2021) Advanced imaging analysis in prostate MRI: building a radiomic signature to predict tumor aggressiveness. Diagnostics (Basel) 11(4):594. https:\/\/doi.org\/10.3390\/diagnostics11040594","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"1541_CR21","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00259-020-05140-y","volume":"48","author":"L Papp","year":"2021","unstructured":"Papp L, Spielvogel CP, Grubmuller B, Grahovac M, Krajnc D, Ecsedi B, Sareshgi RAM, Mohamad D, Hamboeck M, Rausch I, Mitterhauser M, Wadsak W, Haug AR, Kenner L, Mazal P, Susani M, Hartenbach S, Baltzer P, Helbich TH, Kramer G, Shariat SF, Beyer T, Hartenbach M, Hacker M (2021) Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [(68)Ga]Ga-PSMA-11 PET\/MRI. Eur J Nucl Med Mol Imaging 48(6):1795\u20131805. https:\/\/doi.org\/10.1007\/s00259-020-05140-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1541_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00259-021-05430-z","volume":"49","author":"EL Solari","year":"2022","unstructured":"Solari EL, Gafita A, Schachoff S, Bogdanovic B, Villagran Asiares A, Amiel T, Hui W, Rauscher I, Visvikis D, Maurer T, Schwamborn K, Mustafa M, Weber W, Navab N, Eiber M, Hatt M, Nekolla SG (2022) The added value of PSMA PET\/MR radiomics for prostate cancer staging. Eur J Nucl Med Mol Imaging 49(2):527\u2013538. https:\/\/doi.org\/10.1007\/s00259-021-05430-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1541_CR23","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1007\/s00330-020-07617-8","volume":"31","author":"P Alongi","year":"2021","unstructured":"Alongi P, Stefano A, Comelli A, Laudicella R, Scalisi S, Arnone G, Barone S, Spada M, Purpura P, Bartolotta TV, Midiri M, Lagalla R, Russo G (2021) Radiomics analysis of 18F-Choline PET\/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients. Eur Radiol 31(7):4595\u20134605. https:\/\/doi.org\/10.1007\/s00330-020-07617-8","journal-title":"Eur Radiol"},{"issue":"9","key":"1541_CR24","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.7150\/thno.32376","volume":"9","author":"C Zamboglou","year":"2019","unstructured":"Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, Bronsert P, Koeber G, Schilling O, Ruf J, Werner M, Jilg CA, Baltas D, Mix M, Grosu AL (2019) Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer\u2014a comparison study with histology reference. Theranostics 9(9):2595\u20132605. https:\/\/doi.org\/10.7150\/thno.32376","journal-title":"Theranostics"},{"issue":"2","key":"1541_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00259-020-04971-z","volume":"48","author":"MCF Cysouw","year":"2021","unstructured":"Cysouw MCF, Jansen BHE, van de Brug T, Oprea-Lager DE, Pfaehler E, de Vries BM, van Moorselaar RJA, Hoekstra OS, Vis AN, Boellaard R (2021) Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. Eur J Nucl Med Mol Imaging 48(2):340\u2013349. https:\/\/doi.org\/10.1007\/s00259-020-04971-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1541_CR26","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1002\/mp.15064","volume":"48","author":"SJ Tu","year":"2021","unstructured":"Tu SJ, Tran VT, Teo JM, Chong WC, Tseng JR (2021) Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous (11) C-choline PET\/MRI acquisition in prostate cancer patients. Med Phys 48(9):5192\u20135201. https:\/\/doi.org\/10.1002\/mp.15064","journal-title":"Med Phys"},{"issue":"8","key":"1541_CR27","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00259-016-3346-0","volume":"43","author":"F Giesel","year":"2016","unstructured":"Giesel F, Sterzing F, Schlemmer H, Holland-Letz T, Mier W, Rius M, Afshar-Oromieh A, Kopka K, Debus J, Haberkorn U, Kratochwil C (2016) Intra-individual comparison of (68)Ga-PSMA-11-PET\/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 43(8):1400\u20131406. https:\/\/doi.org\/10.1007\/s00259-016-3346-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1541_CR28","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.7150\/thno.15344","volume":"6","author":"C Zamboglou","year":"2016","unstructured":"Zamboglou C, Schiller F, Fechter T, Wieser G, Jilg CA, Chirindel A, Salman N, Drendel V, Werner M, Mix M, Meyer PT, Grosu AL (2016) (68)Ga-HBED-CC-PSMA PET\/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison. Theranostics 6(10):1619\u20131628. https:\/\/doi.org\/10.7150\/thno.15344","journal-title":"Theranostics"},{"key":"1541_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","volume":"141","author":"AS Bettermann","year":"2019","unstructured":"Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, Fassbender TF, Bronsert P, Nicolay NH, Gratzke C, Bock M, Ruf J, Benndorf M, Grosu AL (2019) [(68)Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard\u2014implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol 141:214\u2013219. https:\/\/doi.org\/10.1016\/j.radonc.2019.07.005","journal-title":"Radiother Oncol"},{"issue":"12","key":"1541_CR30","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.2967\/jnumed.115.163741","volume":"56","author":"E Incerti","year":"2015","unstructured":"Incerti E, Fodor A, Mapelli P, Fiorino C, Alongi P, Kirienko M, Giovacchini G, Busnardo E, Gianolli L, Di Muzio N, Picchio M (2015) Radiation treatment of lymph node recurrence from prostate cancer: Is 11C-choline PET\/CT predictive of survival outcomes? J Nucl Med 56(12):1836\u20131842. https:\/\/doi.org\/10.2967\/jnumed.115.163741","journal-title":"J Nucl Med"},{"key":"1541_CR31","unstructured":"Zwanenburg A, Leger S, Valli\u00e8res M, L\u00f6ck S, Initiative F (2016) Image biomarker standardisation initiative"},{"issue":"6","key":"1541_CR32","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00259-020-05111-3","volume":"48","author":"C Zamboglou","year":"2021","unstructured":"Zamboglou C, Bettermann AS, Gratzke C, Mix M, Ruf J, Kiefer S, Jilg CA, Benndorf M, Spohn S, Fassbender TF, Bronsert P, Chen M, Guo H, Wang F, Qiu X, Grosu AL (2021) Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer. Eur J Nucl Med Mol Imaging 48(6):1987\u20131997. https:\/\/doi.org\/10.1007\/s00259-020-05111-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1541_CR33","doi-asserted-by":"publisher","first-page":"600690","DOI":"10.3389\/fonc.2020.600690","volume":"10","author":"SKB Spohn","year":"2020","unstructured":"Spohn SKB, Kramer M, Kiefer S, Bronsert P, Sigle A, Schultze-Seemann W, Jilg CA, Sprave T, Ceci L, Fassbender TF, Nicolay NH, Ruf J, Grosu AL, Zamboglou C (2020) Comparison of manual and semi-automatic [(18)F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference. Front Oncol 10:600690. https:\/\/doi.org\/10.3389\/fonc.2020.600690","journal-title":"Front Oncol"},{"issue":"2","key":"1541_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1142\/s0219720005001004","volume":"3","author":"C Ding","year":"2005","unstructured":"Ding C, Peng H (2005) Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol 3(2):185\u2013205. https:\/\/doi.org\/10.1142\/s0219720005001004","journal-title":"J Bioinform Comput Biol"},{"issue":"8","key":"1541_CR35","doi-asserted-by":"publisher","first-page":"e621","DOI":"10.1016\/j.crad.2021.03.003","volume":"76","author":"D Zhu","year":"2021","unstructured":"Zhu D, Zhang M, Li Q, Liu J, Zhuang Y, Chen Q, Chen C, Xiang Y, Zhang Y, Yang Y (2021) Can perihaematomal radiomics features predict haematoma expansion? Clin Radiol 76(8):e621\u2013e629. https:\/\/doi.org\/10.1016\/j.crad.2021.03.003","journal-title":"Clin Radiol"},{"issue":"Suppl 6","key":"1541_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/annonc\/mdt208","volume":"24","author":"A Horwich","year":"2013","unstructured":"Horwich A, Parker C, de Reijke T, Kataja V, Group EGW (2013) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):106\u2013114. https:\/\/doi.org\/10.1093\/annonc\/mdt208","journal-title":"Ann Oncol"},{"key":"1541_CR37","doi-asserted-by":"publisher","first-page":"839621","DOI":"10.3389\/fonc.2022.839621","volume":"12","author":"X Fan","year":"2022","unstructured":"Fan X, Xie N, Chen J, Li T, Cao R, Yu H, He M, Wang Z, Wang Y, Liu H, Wang H, Yin X (2022) Multiparametric MRI and machine learning based radiomic models for preoperative prediction of multiple biological characteristics in prostate cancer. Front Oncol 12:839621. https:\/\/doi.org\/10.3389\/fonc.2022.839621","journal-title":"Front Oncol"},{"issue":"7","key":"1541_CR38","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.10039.x","volume":"108","author":"V Mouraviev","year":"2011","unstructured":"Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ (2011) Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int 108(7):1074\u20131085. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.10039.x","journal-title":"BJU Int"},{"issue":"1","key":"1541_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 70(1):106\u2013119. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.028","journal-title":"Eur Urol"},{"issue":"3","key":"1541_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-f","volume":"23","author":"DF Gleason","year":"1992","unstructured":"Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23(3):273\u2013279. https:\/\/doi.org\/10.1016\/0046-8177(92)90108-f","journal-title":"Hum Pathol"},{"issue":"4","key":"1541_CR41","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/s0022-5347(05)00734-2","volume":"175","author":"O Andr\u00e9n","year":"2006","unstructured":"Andr\u00e9n O, Fall K, Franz\u00e9n L, Andersson SO, Johansson JE, Rubin MA (2006) How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 175(4):1337\u20131340. https:\/\/doi.org\/10.1016\/s0022-5347(05)00734-2","journal-title":"J Urol"},{"issue":"21","key":"1541_CR42","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2008.20.4669","volume":"27","author":"JR Stark","year":"2009","unstructured":"Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA (2009) Gleason score and lethal prostate cancer: Does 3 + 4 = 4 + 3? J Clin Oncol 27(21):3459\u20133464. https:\/\/doi.org\/10.1200\/JCO.2008.20.4669","journal-title":"J Clin Oncol"},{"issue":"12","key":"1541_CR43","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1007\/s00259-021-05381-5","volume":"48","author":"Y Hou","year":"2021","unstructured":"Hou Y, Zhang YH, Bao J, Bao ML, Yang G, Shi HB, Song Y, Zhang YD (2021) Artificial intelligence is a promising prospect for the detection of prostate cancer extracapsular extension with mpMRI: a two-center comparative study. Eur J Nucl Med Mol Imaging 48(12):3805\u20133816. https:\/\/doi.org\/10.1007\/s00259-021-05381-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1541_CR44","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Schafers M, Shah V, Xu Z, Chabin G, Grbic S, Spottiswoode B, Rahbar K (2020) Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med 61(12):1786\u20131792. https:\/\/doi.org\/10.2967\/jnumed.120.242057","journal-title":"J Nucl Med"},{"issue":"2","key":"1541_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/cancers14020270","volume":"14","author":"PW Mihatsch","year":"2022","unstructured":"Mihatsch PW, Beissert M, Pomper MG, Bley TA, Seitz AK, Kubler H, Buck AK, Rowe SP, Serfling SE, Hartrampf PE, Werner RA (2022) Changing threshold-based segmentation has no relevant impact on semi-quantification in the context of structured reporting for PSMA-PET\/CT. Cancers (Basel) 14(2):270. https:\/\/doi.org\/10.3390\/cancers14020270","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1541_CR46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita A, Bieth M, Kr\u00f6nke M, Tetteh G, Navarro F, Wang H, G\u00fcnther E, Menze B, Weber WA, Eiber M (2019) qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET\/CT. J Nucl Med 60(9):1277\u20131283. https:\/\/doi.org\/10.2967\/jnumed.118.224055","journal-title":"J Nucl Med"},{"issue":"11","key":"1541_CR47","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","volume":"45","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Schmidt D, B\u00e4uerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P (2018) (68)Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 45(11):1862\u20131872. https:\/\/doi.org\/10.1007\/s00259-018-4042-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1541_CR48","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T (2017) Initial experience with volumetric (68)Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 58(12):1962\u20131968. https:\/\/doi.org\/10.2967\/jnumed.117.193581","journal-title":"J Nucl Med"},{"issue":"4","key":"1541_CR49","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00259-020-05059-4","volume":"48","author":"C Draulans","year":"2021","unstructured":"Draulans C, De Roover R, van der Heide UA, Kerkmeijer L, Smeenk RJ, Pos F, Vogel WV, Nagarajah J, Janssen M, Isebaert S, Maes F, Mai C, Oyen R, Joniau S, Kunze-Busch M, Goffin K, Haustermans K (2021) Optimal (68)Ga-PSMA and (18)F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. Eur J Nucl Med Mol Imaging 48(4):1211\u20131218. https:\/\/doi.org\/10.1007\/s00259-020-05059-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1541_CR50","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","volume":"11","author":"AJ Chang","year":"2014","unstructured":"Chang AJ, Autio KA, Roach M 3rd, Scher HI (2014) High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 11(6):308\u2013323. https:\/\/doi.org\/10.1038\/nrclinonc.2014.68","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1541_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.critrevonc.2011.10.003","volume":"83","author":"CH Bangma","year":"2012","unstructured":"Bangma CH, Roobol MJ (2012) Defining and predicting indolent and low risk prostate cancer. Crit Rev Oncol Hematol 83(2):235\u2013241. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.10.003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1541_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/gerona\/gls135","volume":"68","author":"BT Howrey","year":"2013","unstructured":"Howrey BT, Kuo YF, Lin YL, Goodwin JS (2013) The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol Ser A Biol Sci Med Sci 68(1):56\u201361. https:\/\/doi.org\/10.1093\/gerona\/gls135","journal-title":"J Gerontol Ser A Biol Sci Med Sci"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-022-01541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-022-01541-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-022-01541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:02:55Z","timestamp":1664182975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-022-01541-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s11547-022-01541-1","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}